
Core Insights - Daxor Corporation has achieved FDA 510(k) clearance for its next-generation, rapid, compact, hand-held Blood Volume Analyzer (BVA), marking a significant milestone for the company [1] - The Nasdaq Closing Bell Ceremony held on August 8, 2025, celebrated this achievement and is now available for replay [2] Company Overview - Daxor Corporation is addressing a critical issue in healthcare, specifically the inability to accurately measure blood volume, which can lead to suboptimal patient care and increased hospital stays for conditions like heart failure [3] - The company has over 50 years of experience in innovation and offers a patented, FDA-cleared Blood Volume Analysis diagnostic that provides real-time, precise data, enabling clinicians to make better treatment decisions [3] - Daxor operates a state-of-the-art 20,000-square-foot manufacturing facility in the U.S. and is ISO certified, positioning itself for market expansion [3]